Monoclonal Gammopathy Of Undetermined Significance
What's New
Last Posted: May 29, 2023
- Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
David F Moreno, et al. Hematology/oncology clinics of North America 2023 0 - Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Francesca Castellani, et al. Neurology(R) neuroimmunology & neuroinflammation 2023 0 (4) - Detection of complex genomic signatures associated with risk in plasma cell disorders.
Berry Nadine K, et al. Cancer genetics 2017 0 1-9 - Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
Nakamura Ayako, et al. PloS one 2019 0 (9) e0221941 - A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Varettoni Marzia, et al. British journal of haematology 2019 0 (4) 441-446 - Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
Bustoros Mark, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 0 (21) 2380-2389 - Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma.
Rangel-Pozzo Aline, et al. Cancers 2021 0 (8) - Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance.
Alexander J Ryu et al. Blood cancer journal 2023 13(1) 28 - Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
Gayet Mylene, et al. Cytometry. Part B, Clinical cytometry 2021 0 (1) 62-69 - Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
Oben Bénedith, et al. Nature communications 2021 0 (1) 1861 - Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.
Testa Stefano, et al. Seminars in oncology 2022 0 - Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Moreno David F, et al. British journal of haematology 2022 0 (2) 187-196 - A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort.
Baak Lisa, et al. Scientific reports 2022 0 (1) 4409 - Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.
Jiménez Cristina, et al. Annals of hematology 2018 0 (3) 475-484 - Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma.
Grass Sandra, et al. Cancer science 2011 0 (3) 565-8 - The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.
Oben Bénedith, et al. Cancers 2022 0 (4) - Schnitzler syndrome and Schnitzler-like syndromes.
Chu Cong-Qiu, et al. Chinese medical journal 2022 0 (10) 1190-1202 - Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance.
Clay-Gilmour Alyssa I, et al. Blood advances 2020 6 (12) 2789-2797 - Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
Maura Francesco et al. JAMA oncology 2019 Dec - Genetic and transcriptional landscape of plasma cells in POEMS syndrome.
Nagao Yuhei, et al. Leukemia 2019 1
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 03, 2024
- Content source: